pH-Responsive Nanoparticle Vaccines for Dual-Delivery of Antigens and Immunostimulatory Oligonucleotides
Source abstract
Abstract
Protein subunit vaccines offer important potential advantages over live vaccine vectors but generally elicit weaker and shorter-lived cellular immune responses. Here we investigate the use of pH-responsive, endosomolytic polymer nanoparticles that were originally developed for RNA delivery as vaccine delivery vehicles for enhancing cellular and humoral immune responses. Micellar nanoparticles were assembled from amphiphilic diblock copolymers composed of an ampholytic core-forming block and a redesigned polycationic corona block doped with thiol-reactive pyridyl disulfide groups to enable dual-delivery of antigens and immunostimulatory CpG oligodeoxynucleotide (CpG ODN) adjuvants. Polymers assembled into 23 nm particles with simultaneous packaging of CpG ODN and a thiolated protein antigen, ovalbumin (ova). Conjugation of ova to nanoparticles significantly enhanced antigen cross-presentation in vitro relative to free ova or an unconjugated, physical mixture of the parent compounds. Subcutaneous vaccination of mice with ova-nanoparticle conjugates elicited a significantly higher CD8(+) T cell response (0.5% IFN-γ(+) of CD8(+)) compared to mice vaccinated with free ova or a physical mixture of the two components. Significantly, immunization with ova-nanoparticle conjugates electrostatically complexed with CpG ODN (dual-delivery) enhanced CD8(+) T cell responses (3.4% IFN-γ(+) of CD8(+)) 7-, 18-, and 8-fold relative to immunization with conjugates, ova administered with free CpG, or a formulation containing free ova and CpG complexed to micelles, respectively. Similarly, dual-delivery carriers significantly increased CD4(+)IFN-γ(+) (Th1) responses and elicited a balanced IgG1/IgG2c antibody response. Intradermal administration further augmented cellular immune responses, with dual-delivery carriers inducing ∼7% antigen-specific CD8(+) T cells. This work demonstrates the ability of pH-responsive, endosomolytic nanoparticles to actively promote antigen cross-presentation and augment cellular and humoral immune responses via dual-delivery of protein antigens and CpG ODN. Hence, pH-responsive polymeric nanoparticles offer promise as a delivery platform for protein subunit vaccines.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · Immune Response and Inflammation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Bioengineering, University of Washington, Seattle, Washington 98195, United States
References (82)
Show source-provided references
1. Black M. · Expert Rev. Vaccines · 2010 · 9 · 15710.1586/erv.09.160 ↗
2. Perrie Y. · Int. J. Pharm. · 2008 · 364 · 27210.1016/j.ijpharm.2008.04.036 ↗
3. Moon J. J. · Adv. Mater. · 2012 · 24 · 372410.1002/adma.201200446 ↗
4. Ahmed S. S. · Sci. Transl. Med. · 2011 · 3 · 93rv210.1126/scitranslmed.3002302 ↗
5. Hubbell J. A. · Nature · 2009 · 462 · 44910.1038/nature08604 ↗
6. De Temmerman M.-L. · Drug Discovery Today · 2011 · 16 · 56910.1016/j.drudis.2011.04.006 ↗
7. Foged C. · Eur. J. Pharm. Sci. · 2012 · 45 · 48210.1016/j.ejps.2011.08.016 ↗
8. Yewdell J. W. · Curr. Opin. Immunol. · 2010 · 22 · 40210.1016/j.coi.2010.04.002 ↗
9. Amigorena S. · Curr. Opin. Immunol. · 2010 · 22 · 10910.1016/j.coi.2010.01.022 ↗
10. Zhang N. · Immunity · 2011 · 35 · 16110.1016/j.immuni.2011.07.010 ↗
11. Liu M. A. · Immunity · 2010 · 33 · 50410.1016/j.immuni.2010.10.004 ↗
12. Moon J. J. · Nat. Mater. · 2011 · 10 · 24310.1038/nmat2960 ↗
13. Reddy S. T. · Nat. Biotechnol. · 2007 · 25 · 115910.1038/nbt1332 ↗
14. Nembrini C. · Proc. Natl. Acad. Sci. U.S.A. · 2011 · 108 · E98910.1073/pnas.1104264108 ↗
15. Kwon Y. J. · Proc. Natl. Acad. Sci. U.S.A. · 2005 · 102 · 1826410.1073/pnas.0509541102 ↗
16. Kasturi S. P. · Nature · 2011 · 470 · 54310.1038/nature09737 ↗
17. Lee I.-H. · Angew. Chem., Int. Ed. · 2012 · 51 · 880010.1002/anie.201203193 ↗
18. Scott E. A. · Biomaterials · 2012 · 33 · 621110.1016/j.biomaterials.2012.04.060 ↗
19. Andrews C. D. · Mol. Pharmaceutics · 2012 · 9 · 111810.1021/mp2003835 ↗
20. Beaudette T. T. · Mol. Pharmaceutics · 2009 · 6 · 116010.1021/mp900038e ↗
21. Schlosser E. · Vaccine · 2008 · 26 · 162610.1016/j.vaccine.2008.01.030 ↗
22. Gruenberg J. · Nat. Rev. Mol. Cell Biol. · 2006 · 7 · 49510.1038/nrm1959 ↗
23. Cho Y. W. · J. Pharm. Pharmacol. · 2003 · 55 · 72110.1211/002235703765951311 ↗
24. Flanary S. · Bioconjugate Chem. · 2009 · 20 · 24110.1021/bc800317a ↗
25. Foster S. · Bioconjugate Chem. · 2010 · 21 · 220510.1021/bc100204m ↗
26. Convertine A. J. · J. Controlled Release · 2009 · 133 · 22110.1016/j.jconrel.2008.10.004 ↗
27. Convertine A. J. · Biomacromolecules · 2010 · 11 · 290410.1021/bm100652w ↗
28. Bode C. · Expert Rev. Vaccines · 2011 · 10 · 49910.1586/erv.10.174 ↗
29. Krieg A. M. · Nat. Rev. Drug Discovery · 2006 · 5 · 47110.1038/nrd2059 ↗
30. Szablan Z. · J. Polym. Sci., Part A: Polym. Chem. · 2006 · 44 · 369210.1002/pola.21470 ↗
31. Szablan Z. · J. Polym. Sci., Part A: Polym. Chem. · 2004 · 42 · 243210.1002/pola.20098 ↗
32. Bioley G. · Biomaterials · 2012 · 33 · 593510.1016/j.biomaterials.2012.05.004 ↗
33. Fothergill L. A. · Biochem. J. · 1970 · 116 · 55510.1042/bj1160555 ↗
34. Schafer F. Q. · Free Radical Biol. Med. · 2001 · 30 · 119110.1016/S0891-5849(01)00480-4 ↗
35. Hirosue S. · Vaccine · 2010 · 28 · 789710.1016/j.vaccine.2010.09.077 ↗
36. Wendorf J. · J. Pharm. Sci. · 2006 · 95 · 273810.1002/jps.20728 ↗
37. Demento S. L. · Trends Biotechnol. · 2011 · 29 · 29410.1016/j.tibtech.2011.02.004 ↗
38. Krishnamachari Y. · Adv. Drug Delivery Rev. · 2009 · 61 · 20510.1016/j.addr.2008.12.013 ↗
39. Shen Z. · J. Immunol. · 1997 · 158 · 272310.4049/jimmunol.158.6.2723 ↗
40. West M. A. · J. Cell Biol. · 1989 · 109 · 273110.1083/jcb.109.6.2731 ↗
41. Aoki T. · Exp. Cell Res. · 1999 · 253 · 62910.1006/excr.1999.4652 ↗
42. Wang L. H. · J. Cell Biol. · 1993 · 123 · 110710.1083/jcb.123.5.1107 ↗
43. Sallusto F. · J. Exp. Med. · 1995 · 182 · 38910.1084/jem.182.2.389 ↗
44. Sandgren K. J. · PLoS Pathog. · 2010 · 6 · e100086610.1371/journal.ppat.1000866 ↗
45. Burgdorf S. · Curr. Opin. Immunol. · 2008 · 20 · 8910.1016/j.coi.2007.12.002 ↗
46. Akinc A. · Biotechnol. Bioeng. · 2002 · 78 · 50310.1002/bit.20215 ↗
47. Accapezzato D. · J. Exp. Med. · 2005 · 202 · 81710.1084/jem.20051106 ↗
48. Martin R. M. · J. Immunol. Methods · 1998 · 212 · 18710.1016/S0022-1759(98)00015-5 ↗
49. Maubant S. · Nucleic Acid Ther. · 2011 · 21 · 23110.1089/nat.2011.0291 ↗
50. Lührs P. · J. Immunol. · 2002 · 169 · 521710.4049/jimmunol.169.9.5217 ↗
51. Matzelle M. M. · Biomaterials · 2004 · 25 · 29510.1016/S0142-9612(03)00531-3 ↗
52. Wegmann F. · Nat. Biotechnol. · 2012 · 30 · 88310.1038/nbt.2344 ↗
53. Amorij J.-P. · J. Controlled Release · 2012 · 161 · 36310.1016/j.jconrel.2011.12.039 ↗
54. Reed S. G. · Trends Immunol. · 2009 · 30 · 2310.1016/j.it.2008.09.006 ↗
55. Vollmer J. · Adv. Drug Delivery Rev. · 2009 · 61 · 19510.1016/j.addr.2008.12.008 ↗
56. Sablan B. P. · Vaccine · 2012 · 30 · 268910.1016/j.vaccine.2012.02.001 ↗
57. Nierkens S. · Cancer Res. · 2008 · 68 · 539010.1158/0008-5472.CAN-07-6023 ↗
58. Cho H. J. · Nat. Biotechnol. · 2000 · 18 · 50910.1038/75365 ↗
59. Lee J. · Proc. Natl. Acad. Sci. U.S.A. · 2011 · 108 · 1405510.1073/pnas.1105777108 ↗
60. Chen H. C. · Biomaterials · 2011 · 32 · 173110.1016/j.biomaterials.2010.10.059 ↗
61. Honda K. · Nature · 2005 · 434 · 103510.1038/nature03547 ↗
62. Paludan C. · Science · 2005 · 307 · 59310.1126/science.1104904 ↗
63. Schmid D. · Immunity · 2007 · 26 · 7910.1016/j.immuni.2006.10.018 ↗
64. Dengjel J. · Proc. Natl. Acad. Sci. U.S.A. · 2005 · 102 · 792210.1073/pnas.0501190102 ↗
65. Lee H. K. · Science · 2007 · 315 · 139810.1126/science.1136880 ↗
66. Bertin S. · Autophagy · 2008 · 4 · 108610.4161/auto.7138 ↗
67. Combadiere B. · Hum. Vaccines · 2011 · 7 · 81110.4161/hv.7.8.16274 ↗
68. Romani N. · Curr. Top. Microbiol. Immunol. · 2012 · 351 · 113
69. Mohanan D. · J. Controlled Release · 2010 · 147 · 34210.1016/j.jconrel.2010.08.012 ↗
70. Eby J. K. · Acta Biomater. · 2012 · 8 · 321010.1016/j.actbio.2012.06.007 ↗
71. Sheng K.-C. · Eur. J. Immunol. · 2008 · 38 · 42410.1002/eji.200737578 ↗
72. Kar U. K. · PLoS One · 2012 · 7 · e3855310.1371/journal.pone.0038553 ↗
73. Bulmus V. · J. Controlled Release · 2003 · 93 · 10510.1016/j.jconrel.2003.06.001 ↗
74. Murthy N. · Bioconjugate Chem. · 2003 · 14 · 41210.1021/bc020056d ↗
75. Broaders K. E. · Proc. Natl. Acad. Sci. U.S.A. · 2009 · 106 · 549710.1073/pnas.0901592106 ↗
76. Karttunen J. · Proc. Natl. Acad. Sci. U.S.A. · 1992 · 89 · 62010.1073/pnas.89.13.6020 ↗
77. Belizaire R. · Proc. Natl. Acad. Sci. U.S.A. · 2009 · 106 · 1746310.1073/pnas.0908583106 ↗
78. Schwarz K. · J. Immunol. · 2000 · 164 · 614710.4049/jimmunol.164.12.6147 ↗
79. Gerelchuluun T. · Arch. Pharmacol. Res. · 2007 · 30 · 144010.1007/BF02977369 ↗
80. Murthy N. · J. Controlled Release · 1999 · 61 · 13710.1016/S0168-3659(99)00114-5 ↗
81. De Koker S. · Angew. Chem., Int. Ed. · 2009 · 48 · 848510.1002/anie.200903769 ↗
82. Brito L. A. · J. Pharm. Sci. · 2010 · 100 · 3410.1002/jps.22267 ↗